Roka Bioscience enjoys the full faith and financial confidence of key investment companies who specialize in healthcare-focused opportunities.
OrbiMed is a leading investment firm dedicated exclusively to the healthcare sector. With $7 billion in assets under management, OrbiMed invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies. OrbiMed’s team manages a series of private equity funds, public equity funds, royalty and debt funds, and other investment vehicles. For more information, go to www.orbimed.com.
TPG Biotech is part of the growth equity and venture investment platform of TPG, the global private investment firm. With more than $1 billion under management, TPG Biotech targets investments in pharmaceutical discovery and development, medical technology, diagnostics, healthcare and pharmaceutical services, life sciences, as well as industrial applications of biotechnology. For more information, go to www.tpg.com.
New Enterprise Associates, Inc. (NEA) is a leading venture capital and growth equity firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With approximately $11 billion in committed capital, NEA invests in information technology, healthcare and energy technology companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm’s long track record of successful investing includes more than 165 portfolio company IPOs and more than 280 acquisitions. In the U.S., NEA has two offices in the Washington, D.C. metropolitan area and one in Menlo Park, California. In addition, New Enterprise Associates (India) Pvt. Ltd. has offices in Bangalore and Mumbai, India and New Enterprise Associates (Beijing), Ltd. has offices in Beijing and Shanghai, China. For more information, go to www.nea.com.
Aisling Capital is a dedicated life sciences private equity firm with over US$1.6 billion under management. Headquartered in New York, Aisling Capital invests in both private and public companies utilizing a wide variety of investment structures. The Aisling Capital team’s combination of clinical, operational and financial experience allows the firm to identify, execute and realize investments across the life sciences industry. For more information, go to www.aislingcapital.com.